Status:
UNKNOWN
Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma
Lead Sponsor:
Assiut University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-65 years
Brief Summary
Hepatocellular carcinoma represents the commonest primary cancer of the liver.serum lactate dehydrogenase is an indirect marker of tumor hypoxia,angioneogenesis and worse prognosis.
Detailed Description
Hepatocellular carcinoma (HCC) represents the commonest primary cancer of the liver. Incidence is increasing and HCC has risen to become the 5th commonest malignancy worldwide and the third leading ca...
Eligibility Criteria
Inclusion
- patients with Hepatocellular carcinoma diagnosed by biopsy or imaging criteria and alpha feto protein.
- signed informed consent before registration in study
- Eastern Cooperative oncology Groups Performance status between 0 and 2.
Exclusion
- Cachexia or poor condition
- pregnant or human chorionic gonadotropin positive
- patient with another liver tumor
- Any previous treatment
Key Trial Info
Start Date :
January 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03338166
Start Date
January 2 2018
End Date
December 1 2018
Last Update
November 9 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.